| Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial YH Kim, M Bagot, L Pinter-Brown, AH Rook, P Porcu, SM Horwitz, ... The lancet oncology 19 (9), 1192-1204, 2018 | 542 | 2018 |
| Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis AM Petrich, M Gandhi, B Jovanovic, JJ Castillo, S Rajguru, DT Yang, ... Blood, The Journal of the American Society of Hematology 124 (15), 2354-2361, 2014 | 526 | 2014 |
| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 371 | 2021 |
| Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial NN Shah, BD Johnson, D Schneider, F Zhu, A Szabo, CA Keever-Taylor, ... Nature medicine 26 (10), 1569-1575, 2020 | 367 | 2020 |
| Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors AS Kanate, A Mussetti, MA Kharfan-Dabaja, KW Ahn, A DiGilio, ... Blood, The Journal of the American Society of Hematology 127 (7), 938-947, 2016 | 291 | 2016 |
| PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD BM Haverkos, D Abbott, M Hamadani, P Armand, ME Flowers, ... Blood, The Journal of the American Society of Hematology 130 (2), 221-228, 2017 | 278 | 2017 |
| Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma SM Smith, LJ Burns, K van Besien, J LeRademacher, W He, TS Fenske, ... Journal of Clinical Oncology 31 (25), 3100, 2013 | 263 | 2013 |
| Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant … N Ghosh, R Karmali, V Rocha, KW Ahn, A DiGilio, PN Hari, V Bachanova, ... Journal of Clinical Oncology 34 (26), 3141, 2016 | 250 | 2016 |
| A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma TA Fehniger, S Larson, K Trinkaus, MJ Siegel, AF Cashen, KA Blum, ... Blood, The Journal of the American Society of Hematology 118 (19), 5119-5125, 2011 | 221 | 2011 |
| Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first … HA Burris, IW Flinn, MR Patel, TS Fenske, C Deng, DM Brander, ... The Lancet Oncology 19 (4), 486-496, 2018 | 218 | 2018 |
| Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell … JM Vose, S Carter, LJ Burns, E Ayala, OW Press, CH Moskowitz, ... Journal of Clinical Oncology 31 (13), 1662, 2013 | 193 | 2013 |
| Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort … MA Kharfan-Dabaja, A Kumar, E Ayala, M Hamadani, P Reimer, ... Biology of Blood and Marrow Transplantation 23 (11), 1826-1838, 2017 | 168 | 2017 |
| Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing … TS Fenske, MJ Zhang, J Carreras, E Ayala, LJ Burns, A Cashen, LJ Costa, ... Journal of clinical oncology 32 (4), 273, 2014 | 167 | 2014 |
| Outcomes of patients with double-hit lymphoma who achieve first complete remission DJ Landsburg, MK Falkiewicz, J Maly, KA Blum, C Howlett, T Feldman, ... Journal of Clinical Oncology 35 (20), 2260, 2017 | 166 | 2017 |
| Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation M Hamadani, PN Hari, Y Zhang, J Carreras, G Akpek, MD Aljurf, E Ayala, ... Biology of Blood and Marrow Transplantation 20 (11), 1729-1736, 2014 | 152 | 2014 |
| Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? U Bacher, E Klyuchnikov, J Le-Rademacher, J Carreras, P Armand, ... Blood, The Journal of the American Society of Hematology 120 (20), 4256-4262, 2012 | 152 | 2012 |
| Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis C Casulo, JW Friedberg, KW Ahn, C Flowers, A DiGilio, SM Smith, ... Biology of blood and marrow transplantation 24 (6), 1163-1171, 2018 | 151 | 2018 |
| Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation TS Fenske, KW Ahn, TM Graff, A DiGilio, Q Bashir, RT Kamble, E Ayala, ... British journal of haematology 174 (2), 235-248, 2016 | 144 | 2016 |
| Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice TS Fenske, G Pengue, V Mathews, PT Hanson, SE Hamm, N Riaz, ... Proceedings of the National Academy of Sciences 101 (42), 15184-15189, 2004 | 121 | 2004 |
| Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy B Dhakal, S Abedin, T Fenske, S Chhabra, N Ledeboer, P Hari, ... Blood, The Journal of the American Society of Hematology 138 (14), 1278-1281, 2021 | 118 | 2021 |
